Lanean...
Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy
The introduction in the clinic of immune checkpoint inhibitors (IOs) has represented an important improvement for the treatment of patients with advanced non-small cell lung cancer (NSCLC). These drugs have shown a higher activity as compared with chemotherapy in both first- and second-line of treat...
Gorde:
| Argitaratua izan da: | Transl Lung Cancer Res |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
AME Publishing Company
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6249618/ https://ncbi.nlm.nih.gov/pubmed/30505711 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2018.09.23 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|